SEC Tracker
Get the app

Nanoviricides NNVC

Nanoviricides FY 2022: net loss $8.1M; diluted EPS −$0.70

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Nanoviricides reported for the year ended Jun 30, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$8.1MAgainst −$8.8M in FY 202110-K income statement, on EDGAR
  2. Diluted EPS−$0.70Against −$0.81 in FY 202110-K income statement, on EDGAR
  3. Cash and cash equivalents$14.1M−31% from $20.5M in FY 202110-K balance sheet, on EDGAR
  4. Cash from operations−$5.9MAgainst −$8.2M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Nanoviricides files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Lisata Therapeutics LSTA public float $24M, Jun 30, 2025
  2. Tenax Therapeutics TENX public float $24M, Jun 30, 2025
  3. Aytu Biopharma AYTU public float $24M, Dec 31, 2025
  4. Dyadic International DYAI public float $24M, Jun 30, 2025
  5. Kala Bio KALA public float $25M, Jun 30, 2025